Browse NMNAT2

Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Golgi apparatus
Domain PF01467 Cytidylyltransferase-like
Function

Catalyzes the formation of NAD(+) from nicotinamide mononucleotide (NMN) and ATP. Can also use the deamidated form; nicotinic acid mononucleotide (NaMN) as substrate but with a lower efficiency. Cannot use triazofurin monophosphate (TrMP) as substrate. Also catalyzes the reverse reaction, i.e. the pyrophosphorolytic cleavage of NAD(+). For the pyrophosphorolytic activity prefers NAD(+), NADH and NaAD as substrates and degrades nicotinic acid adenine dinucleotide phosphate (NHD) less effectively. Fails to cleave phosphorylated dinucleotides NADP(+), NADPH and NaADP(+).

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006531 aspartate metabolic process
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0009066 aspartate family amino acid metabolic process
GO:0009108 coenzyme biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009435 NAD biosynthetic process
GO:0019355 nicotinamide nucleotide biosynthetic process from aspartate
GO:0019359 nicotinamide nucleotide biosynthetic process
GO:0019362 pyridine nucleotide metabolic process
GO:0019363 pyridine nucleotide biosynthetic process
GO:0019674 NAD metabolic process
GO:0034627 'de novo' NAD biosynthetic process
GO:0034628 'de novo' NAD biosynthetic process from aspartate
GO:0043648 dicarboxylic acid metabolic process
GO:0046496 nicotinamide nucleotide metabolic process
GO:0051186 cofactor metabolic process
GO:0051188 cofactor biosynthetic process
GO:0072524 pyridine-containing compound metabolic process
GO:0072525 pyridine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901605 alpha-amino acid metabolic process
Molecular Function GO:0000309 nicotinamide-nucleotide adenylyltransferase activity
GO:0004515 nicotinate-nucleotide adenylyltransferase activity
GO:0016779 nucleotidyltransferase activity
GO:0070566 adenylyltransferase activity
Cellular Component GO:0005770 late endosome
GO:0005802 trans-Golgi network
GO:0031984 organelle subcompartment
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa00760 Nicotinate and nicotinamide metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-196807: Nicotinate metabolism
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NMNAT2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NMNAT2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NMNAT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0240.928
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3810.432
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3250.457
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5280.171
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.40.747
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6880.644
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1870.742
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2850.735
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0920.918
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5530.587
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5390.684
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6820.0133
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NMNAT2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414250250.222
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NMNAT2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NMNAT2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NMNAT2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NMNAT2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NMNAT2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NMNAT2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNMNAT2
Namenicotinamide nucleotide adenylyltransferase 2
Aliases KIAA0479; PNAT2; C1orf15; chromosome 1 open reading frame 15; NMN adenylyltransferase 2; NMN/NaMN adenylyltr ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NMNAT2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.